Patents Assigned to Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-
Publication number: 20230324396Abstract: Provided are a method for diagnosing nasopharyngeal carcinoma on the basis of the anti-EB virus (EBV) antibody level and a kit used for the method. Also provided are a polypeptide encoded by a BNLF2b gene in EB virus used for the above-mentioned diagnosis and the use thereof for diagnosing nasopharyngeal carcinoma.Type: ApplicationFiled: December 25, 2020Publication date: October 12, 2023Applicants: XIAMEN UNIVERSITY, XIAMEN INNODX BIOTECH CO., LTD, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Tingdong LI, Shengxiang GE, Xiaoyi GUO, Congming HONG, Liuwei SONG, Shunhua WEN, Jiabao TANG, Jun ZHANG, Ningshao XIA
-
Patent number: 11220673Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.Type: GrantFiled: April 13, 2020Date of Patent: January 11, 2022Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Rutgers, The State University of New Jersey, Xiamen UniversityInventors: Hua Zhu, Yimin Li, Ningshao Xia, Tong Cheng, Xiangzhong Ye
-
Patent number: 10864521Abstract: The present invention relates to a detection mechanism for polymerase chain reaction and a polymerase chain reaction device, wherein the detection mechanism comprises at least one excitation module group, each of the excitation module groups comprising two excitation modules for providing excitation light with two wavelengths; an excitation optical fiber, connected to the excitation modules, the excitation optical fiber transmitting the excitation light to at least one reaction tube, each of the reaction tubes receiving excitation light with two wavelengths; a receiving optical fiber, for collecting and transmitting a fluorescent signal from the reaction tube; at least one receiving module group, connected to the receiving optical fiber, each of the receiving module groups comprising two receiving modules, to respectively receive the fluorescent signal of two wavelengths from the same said reaction tube, and convert the fluorescent signal into an electrical signal for output; the detection mechanism is configType: GrantFiled: October 25, 2016Date of Patent: December 15, 2020Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing University of Chemical Technology, Xiamen UniversityInventors: Xianbo Qiu, Xiangzhong Ye, Shengxiang Ge, Shiyin Zhang, Pengfei Gao, Shangzhi Ji, Yongliang Yang, Zixin Qiu, Ningshao Xia
-
Publication number: 20200277577Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.Type: ApplicationFiled: April 13, 2020Publication date: September 3, 2020Applicant: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Hua ZHU, Yimin LI, Ningshao XIA, Tong CHENG, Xiangzhong YE
-
Patent number: 10752885Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.Type: GrantFiled: January 9, 2018Date of Patent: August 25, 2020Assignees: Rutgers, the State University of New Jersey, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Hua Zhu, Yimin Li, Ningshao Xia, Tong Cheng, Xiangzhong Ye
-
Patent number: 9943586Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: November 14, 2016Date of Patent: April 17, 2018Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
-
Patent number: 9885020Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.Type: GrantFiled: July 27, 2010Date of Patent: February 6, 2018Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD., XIAMEN UNIVERSITYInventors: Hua Zhu, Yimin Li, Ningshao Xia, Tong Cheng, Xiangzhong Ye
-
Patent number: 9745351Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the truncated L1 protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: April 8, 2014Date of Patent: August 29, 2017Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Patent number: 9533035Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: May 29, 2008Date of Patent: January 3, 2017Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
-
Patent number: 9428554Abstract: The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No.Type: GrantFiled: April 30, 2009Date of Patent: August 30, 2016Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Ningshao Xia, Jun Zhang, Ying Gu, Shaowei Li, Shengxiang Ge, Zhiqiang He
-
Patent number: 9428555Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.Type: GrantFiled: April 29, 2008Date of Patent: August 30, 2016Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ying Gu, Shaowei Li, Minxi Wei, Yangling Xian, Wenxin Luo, Ningshao Xia
-
Patent number: 9364529Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.Type: GrantFiled: April 29, 2008Date of Patent: June 14, 2016Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Shaowei Li, Wentong Shen, Zhongyi Li, Minghui Xie, Huirong Pan, Ningshao Xia
-
Publication number: 20140288283Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: ApplicationFiled: April 8, 2014Publication date: September 25, 2014Applicants: BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD., XIAMEN UNIVERSITYInventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Patent number: 8748127Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: May 29, 2008Date of Patent: June 10, 2014Assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Patent number: 8715695Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: September 11, 2009Date of Patent: May 6, 2014Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Patent number: 8524868Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: November 9, 2009Date of Patent: September 3, 2013Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Publication number: 20110243904Abstract: The present invention relates to RNA interference target sequence targeting HIV for the treatment of AIDS. Based on the target sequence, recombinant expression vectors, packaging vectors and cells were constructed, which express a siRNA and/or a miRNA and/or a ribozyme and/or an antisense oligonucleotide targeting HIV. Also provided is the use of the recombinant expression vectors, packaging vectors and recombinant cells in the manufacture of a medicament for the treatment of AIDS.Type: ApplicationFiled: June 2, 2008Publication date: October 6, 2011Applicants: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Tong Cheng, Tao Zhang, Yali Zhang, Ji Miao, Jun Zhang, Ningshao Xia
-
Publication number: 20100255021Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: ApplicationFiled: May 29, 2008Publication date: October 7, 2010Applicants: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Patent number: 7786264Abstract: The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No.Type: GrantFiled: November 8, 2002Date of Patent: August 31, 2010Assignee: Beijing Wantai Biological Pharmacy Enterprise Co., LtdInventors: Ningshao Xia, Jun Zhang, Ying Gu, Shaowei Li, Shengxiang Ge, Zhiqiang He
-
Patent number: 7615228Abstract: A purified polypeptide comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of a polymer with n monomeric polypeptides, wherein n is an integer from 2-180; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: September 30, 2001Date of Patent: November 10, 2009Assignee: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He